Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jennifer S. Buell
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Beta
- 0.49
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -26.04
Financials
Net Income
$-3.13MEBITDA
$-3.18MFree Cash Flow
$-2.08MEPS (diluted)
$-0.62Shares Outstanding (diluted)
5.02M+108.6%Operating Expenses
$3.22MCash & Debt
$8.81MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-12.49M | $-2.93 |
| 2024 | $0.00 | $-10.78M | $-2.90 |
| 2023 | $0.00 | $-22.46M | $-6.54 |
| 2022 | $0.00 | $-27.99M | $-8.31 |
| 2021 | $0.00 | $-30.21M | $-9.03 |
| 2020 | $0.00 | $-16.24M | $-4.91 |
| 2019 | $689.6K | $-23.80M | $-7.80 |
Valuation
INKThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
107Social Signal Score
Mentions (3)
- Newsseekingalpha.com·53d ago·Positive
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Neutral
MiNK Therapeutics Q2 Earnings Call Highlights MiNK Therapeutics NASDAQ: INKT said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
…and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune disorders, today reported financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.35 per share
Typical surprise -3.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.62 vs $-0.60miss
- Fri, May 15$-0.57 vs $-0.77beat
- Tue, Mar 17$-0.52 vs $-0.68beat
- Fri, Nov 14$-0.65 vs $-0.86beat
- Thu, Aug 14$-1.06 vs $-0.55miss
- Thu, May 15$-0.70 vs $-0.61miss
Estimates and results for INKT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INKT officers and directors.
- Bought
- $42k
- Sold
- $47k
4 trades
8 trades
- Ryan Barbarasold
- Ryan Barbarasold
- Ryan Barbarasold
- Ryan Barbarasold
- Ryan Barbarasold
- Ryan Barbarasold
- Ryan Barbarasold
- Ryan Barbarasold
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in INKT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.